Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments
Analyst Sam Slutsky from LifeSci Capital maintains a Buy rating on DBV Technologies, with a $19.00 price target, due to promising developments in their VIASKIN Peanut treatment trial. The Phase 3 VITESSE trial, aimed at treating children with peanut allergies, has completed its final patient visit, with topline data expected soon. The trial's larger size and design improvements increase the likelihood of success, potentially leading to accelerated approval and a BLA submission by 2026.
Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on DBV Technologies SA – American and keeping the price target at $19.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sam Slutsky has given his Buy rating due to a combination of factors surrounding DBV Technologies’ promising developments with their VIASKIN Peanut treatment for children aged 4-7 with peanut allergies. The pivotal Phase 3 VITESSE trial has recently completed its final patient visit, and the topline data is expected before the end of the year. The trial aims to demonstrate a significant treatment response, which, if successful, could lead to accelerated approval and a BLA submission planned for the first half of 2026.
Slutsky is optimistic about the trial’s success due to its larger size compared to previous studies and several modifications that increase the likelihood of a positive outcome. The trial’s design improvements, such as changes in inclusion criteria and primary endpoints, are expected to enhance the chances of achieving statistical significance. This positive outlook, combined with the company’s financial positioning and upcoming milestones, underpins the Buy rating for DBV Technologies.
